Immunotherapy News and Research

Latest Immunotherapy News and Research

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.

24 Mar 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology.

23 Mar 2015

Study reveals functional heterogeneity of CD4 T cells in immune systems

Utilizing a novel transgenic mouse model, Edward Usherwood, PhD of Dartmouth's Norris Cotton Cancer Center and collaborators found that CD4 T cells divide into two different populations that each has a different job. One type performs antiviral functions, and the other survives life in the host.

23 Mar 2015

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects.

20 Mar 2015

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes.

20 Mar 2015

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM).

19 Mar 2015

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.

19 Mar 2015

Study reveals novel approach to treat breast cancer

A means of reprogramming a flawed immune response into an efficient anti-tumoral one was brought to light by the results of a translational trial relating to breast cancer. Thanks to the innovative combination of mathematical modelisation and experimentation, only 20 tests were necessary, whereas traditional experimentation would have required 596 tests to obtain the same results.

18 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Comprehensive review of sex hormones' role in female reproductive tract

Charles R. Wira, PhD, and colleagues at Dartmouth's Geisel School of Medicine have presented a comprehensive review of the role of sex hormones in the geography of the female reproductive tract and evidence supporting a "window of vulnerability" to HIV and other sexually transmitted infections (STIs).

17 Mar 2015

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

16 Mar 2015

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists, James P. Allison and Carl H. June, will today receive the Paul Ehrlich and Ludwig Darmstaedter Prize in the Paulskirche in Frankfurt. Both give the patient's own immune system the lasting ability to fight cancer, Allison against late stage melanoma, June against leukemia.

16 Mar 2015

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy.

12 Mar 2015

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.

12 Mar 2015

Wistar awarded grant to create Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium

The Jayne Koskinas Ted Giovanis Foundation awarded The Wistar Institute a $1.1 million grant to create The Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium at The Wistar Institute. The Consortium will support the highly synergistic, multidisciplinary research projects of three Wistar scientists dedicated to advancing breast cancer research.

12 Mar 2015

New method could lead to improved treatment for NPC patients

Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

11 Mar 2015

EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).

9 Mar 2015